Alexis Borisy and Melanie Nallicheri
October 4, 2023 05:12 PM EDTUpdated 05:42 PM
Deals

EQRx had lim­it­ed buy­er in­ter­est, tried ac­quir­ing oth­er com­pa­nies be­fore Rev­o­lu­tion came for its cash

Kyle LaHucik

Biotech Correspondent

In No­vem­ber, EQRx pub­licly gave up on the fi­nal pieces of its low-cost med­i­cines ap­proach. But in a re­cent fi­nan­cial

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Bio­phar­ma lead­ers carv­ing a path for the in­dus­try’s LGBTQ+ com­mu­ni­ty

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times